Influenza Vaccine Enhancement Patch: Phase I data

An open-label, European Phase I trial in 300 healthy volunteers showed that the Influenza VEP in combination with GlaxoSmithKline's H5N1 antigen did not produce a >=2 fold increase in HAI titers vs. G...